Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Free Report) fell 4.6% during trading on Thursday after UBS Group lowered their price target on the stock from $30.00 to $27.00. UBS Group currently has a buy rating on the stock. Teva Pharmaceutical Industries traded as low as $17.62 and last traded at $17.69. 18,918,568 shares were traded during mid-day trading, an increase of 58% from the average session volume of 11,937,447 shares. The stock had previously closed at $18.54.
A number of other brokerages have also commented on TEVA. StockNews.com lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Barclays cut their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday. Piper Sandler boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and an average target price of $22.00.
Read Our Latest Report on Teva Pharmaceutical Industries
Insiders Place Their Bets
Hedge Funds Weigh In On Teva Pharmaceutical Industries
Several institutional investors and hedge funds have recently modified their holdings of TEVA. UMB Bank n.a. grew its stake in shares of Teva Pharmaceutical Industries by 555.6% in the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock valued at $44,000 after acquiring an additional 2,067 shares in the last quarter. Smithfield Trust Co grew its stake in shares of Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after acquiring an additional 980 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Teva Pharmaceutical Industries in the third quarter valued at about $50,000. Claro Advisors LLC acquired a new position in shares of Teva Pharmaceutical Industries in the third quarter valued at about $52,000. Finally, Venturi Wealth Management LLC acquired a new position in shares of Teva Pharmaceutical Industries in the third quarter valued at about $60,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.
Teva Pharmaceutical Industries Price Performance
The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. The company’s 50 day moving average is $19.97 and its 200 day moving average is $18.48. The firm has a market capitalization of $20.25 billion, a price-to-earnings ratio of -21.03, a P/E/G ratio of 1.11 and a beta of 0.73.
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last released its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 5.73% and a positive return on equity of 42.92%. On average, equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.37 earnings per share for the current fiscal year.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
See Also
- Five stocks we like better than Teva Pharmaceutical Industries
- What is a buyback in stocks? A comprehensive guide for investors
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- Technology Stocks Explained: Here’s What to Know About Tech
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Trading Stocks: RSI and Why it’s Useful
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.